TipRanks

Notifications

Tag: ZIOP

Total 8 Posts

H.C. Wainwright Reiterates a Hold Rating on Ziopharm Oncology (ZIOP)

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Hold rating on Ziopharm Oncology (ZIOPResearch Report) on November 15. The company’s shares closed last Friday at $1.43, close to its 52-week low of $1.26.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 24.1% and a 47.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals, Janux Therapeutics Inc, and Corcept Therapeutics.

Currently, the analyst consensus on Ziopharm Oncology is a Hold with an average price target of $1.75, representing a 25.0% upside. In a report issued on November 9, Raymond James also maintained a Hold rating on the stock with a $2.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $5.95 and a one-year low of $1.26. Currently, Ziopharm Oncology has an average volume of 3.28M.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZIOP in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Read More on ZIOP:

H.C. Wainwright Reiterates Their Hold Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Ziopharm Oncology (ZIOPResearch Report). The company’s shares closed last Monday at $1.69, close to its 52-week low of $1.64.

According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 24.1% and a 43.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Janux Therapeutics Inc, and Corvus Pharmaceuticals.

Ziopharm Oncology has an analyst consensus of Moderate Buy, with a price target consensus of $3.25, representing an 85.7% upside. In a report issued on August 9, Raymond James also downgraded the stock to Hold with a $3.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.95 and a one-year low of $1.64. Currently, Ziopharm Oncology has an average volume of 1.68M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Read More on ZIOP: